Viridian Therapeutics, Inc.
VRDNDrugs in Pipeline
5
Phase 3 Programs
5
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
28dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
How VRDN's past catalysts played out
VRDN-001 10 mg/kg
Thyroid Eye Disease
Intervention/Treatment
Thyroid Eye Disease
VRDN-001 Phase 3 Cohort (THRIVE)
Thyroid Eye Disease
Veligrotug (VRDN-001)
Thyroid Eye Disease
VRDN-003
Thyroid Eye Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VRDN-001 10 mg/kg | Phase 3 | Thyroid Eye Disease | - | - |
Intervention/Treatment | Phase 3 | Thyroid Eye Disease | - | - |
VRDN-001 Phase 3 Cohort (THRIVE) | Phase 3 | Thyroid Eye Disease | - | - |
Veligrotug (VRDN-001) | Phase 3 | Thyroid Eye Disease | - | - |
VRDN-003 | Phase 3 | Thyroid Eye Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Viridian Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Viridian Therapeutics, Inc.'s (VRDN) pipeline across Phase 3. Its lead program is VRDN-001 10 mg/kg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Viridian Therapeutics, Inc.'s next FDA catalyst?→
Viridian Therapeutics, Inc.'s (VRDN) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VRDN biotech catalysts?→
Add VRDN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Viridian Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.